June 29, 1999
Scientists use bacterial toxin to kill brain tumours
TORONTO –-Researchers at The Hospital for Sick Children (SickKids) and the University of Toronto (U of T) have used a toxin produced by the same bacteria that cause hamburger disease to completely eliminate malignant human brain tumours grown in mice. The research is published in the June issue of the scientific journal Oncology Research.
"E. coli is a common gastrointestinal bacterium," explains Dr. Cliff Lingwood, a senior scientist at HSC and a Professor of Laboratory Medicine and Pathobiology at the U of T. "Some E. coli strains produce a toxin known as verotoxin. Our earlier research has shown that, in the test tube, verotoxin kills certain brain tumour cells very efficiently. We wanted to determine if this was also the case in a living animal."
As part of her doctoral studies in Dr. Lingwood’s laboratory, Dr. Sara Arab (now a clinical fellow in Medical Genetics at SickKids) injected verotoxin directly into human astrocytoma brain tumours that had been grown in mice. After a single injection, the tumours had shrunk by half within 48 hours. Within seven to 15 days the tumours had completely disappeared and had not reappeared by the end of the experiment (60 days). Both the tumours and their blood vessels were killed by the toxin.
"We are very excited by this observation because astrocytoma is the most common type of malignant brain tumour and the prognosis is poor for patients with this diagnosis," explains SickKids neurosurgeon James Rutka, a collaborator in the research and head of the Arthur and Sonia Labatt Brain Tumour Research Centre. Approximately 20,000 people are diagnosed with brain tumours each year in Canada and the United States. "This discovery could be very promising because the verotoxin makes a two-pronged attack on the tumour: it destroys tumour cells and shuts down the tumour’s blood supply."
While earlier SickKids research has demonstrated that verotoxin-producing E. coli can cause kidney failure, primarily in very young children, the scientists suggest that a window of opportunity exists for verotoxin treatment in older patients.
Plans are already underway for the next phase of the research: preliminary clinical trials in older children and adults. In that trial, verotoxin will be injected into residual glioblastoma cells following surgical removal of the majority of the tumour. Glioblastoma is the most malignant form of astrocytoma.
This research was supported by the Medical Research Council of Canada and The Hospital for Sick Children Foundation. Select Therapeutics Inc. holds an exclusive licensing agreement with The Hospital for Sick Children to bring the benefits of this research to market.
Public Affairs
The Hospital for Sick Children
555 University Avenue
Suite 1742, Public Affairs, First floor Atrium
Toronto,
ON
M5G 1X8
Canada
Phone: 416-813-5058
Fax: 416-813-5328